Author: OurCrowd

[Alloy Therapeutics in BusinessWire] Alloy Therapeutics announces new licensing model for ATX-Gx™ antibody discovery platform and launches mAbForge™ high-throughput screening service

Jan 9, 2025 |

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-Gx™ antibody technology platform with no annual access fee or development milestones. Partners benefit from Alloy as an ever-growing source of pre-competitive, foundational discovery technology. Read...

Read More

[MeMed in Business Wire] MeMed Expands Advisory Board with Key Leaders to Advance Host-Response Diagnostics for Sepsis and AMR

Jan 9, 2025 |

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–MeMed, a leader in host-response diagnostics, today announced the addition of three distinguished experts to its advisory board to accelerate its mission of addressing the global challenges of sepsis and antimicrobial resistance (AMR) through innovative diagnostic solutions. Read more...

Read More

[NeuReality in AI Business] AI’s new wave: Great spaceships, bumpy runways

Jan 9, 2025 |

Even as the AI era has captured the public imagination and inspired countless potential applications, it’s also exposed a critical gap: Current AI data center infrastructure is not equipped to manage the massive computational demands of today’s and tomorrow’s AI applications and models. This mismatch between AI’s true capability and our ability to deploy it effectively is widening, particularly when it comes to inference—the process of putting trained AI models to work in the real business world. Read...

Read More